About Dual specificity protein phosphatase 4
Dual specificity protein phosphatase 4 (DUSP4) is a protein
from Homo sapiens identified by UniProt accession
Q13115, 394 residues long.
MolForge cross-references it against 0 known binders and
776 disease associations.
Target properties
| Protein name | Dual specificity protein phosphatase 4 |
| UniProt accession | Q13115 |
| Gene | DUSP4 |
| Organism | Homo sapiens |
| Length | 394 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (776)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.50
- heel bone mineral density · score 0.35
- protein measurement · score 0.29
- breast adenocarcinoma · score 0.29
- high density lipoprotein cholesterol measurement · score 0.26
- response to statin · score 0.26
- body height · score 0.26
- BMI-adjusted waist circumference · score 0.25
- mammographic density percentage · score 0.19
- cutaneous melanoma · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q13115-F1 | alphafold | PREDICTED | 77.12 | — |
Amino-acid sequence (394 residues)
MVTMEELREM DCSVLKRLMN RDENGGGAGG SGSHGTLGLP SGGKCLLLDC RPFLAHSAGY ILGSVNVRCN TIVRRRAKGS VSLEQILPAE EEVRARLRSG LYSAVIVYDE RSPRAESLRE DSTVSLVVQA LRRNAERTDI CLLKGGYERF SSEYPEFCSK TKALAAIPPP VPPSATEPLD LGCSSCGTPL HDQGGPVEIL PFLYLGSAYH AARRDMLDAL GITALLNVSS DCPNHFEGHY QYKCIPVEDN HKADISSWFM EAIEYIDAVK DCRGRVLVHC QAGISRSATI CLAYLMMKKR VRLEEAFEFV KQRRSIISPN FSFMGQLLQF ESQVLATSCA AEAASPSGPL RERGKTPATP TSQFVFSFPV SVGVHSAPSS LPYLHSPITT SPSC
Explore Dual specificity protein phosphatase 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets